UiPath remains a buy, outperforming the S&P 500 with a 53.6% gain since March 2025, driven by operational turnaround. Click ...

Once thought to be doomed by the AI revolution, robotic process automation specialist UiPath (NYSE: PATH) defied critics in ...

UiPath (NYSE: PATH), a global leader in agentic automation, today announced its UiPath Screen Agent powered by Claude Opus ...

Alphabet, Salesforce, and UiPath all look like good buys right now. Tech stocks continue to lead the market higher, but that ...

UiPath CFO and COO Ashim Gupta outlines why the company’s recent progress rests less on agentic AI re-positioning and more on ...

In early January 2026, UiPath Inc. was added to the S&P 1000 and S&P MidCap 400 indices after reporting earnings that ...

With investors' artificial intelligence focus turning to agentic AI, UiPath stock could be a long-term winner.

UiPath delivered a beat-and-raise quarter and was promoted into a midcap index. Shares of automation software company UiPath ...

Palantir has been one of the best growth stories in the market. UiPath is just beginning to see its revenue growth accelerate as it looks to become an AI agent orchestration platform. UIPath's ...

UiPath is moving beyond simple, rule-based bots toward "agentic automation." Partnerships are helping to drive scalability of this evolving business. UiPath’s focus on security and transparency could ...

ChatGPT thinks UiPath stock could drift lower over the next 60 days, projecting a move toward roughly $16.20 by late March as ...

Testing an AI agent for donor tissue screening at Evergen surfaces more than technical performance questions. The project ...